Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?